$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000147929017000023 Filed on May 09, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$75.00K	$75.00K	$75.00K
YoY Change	0.0%	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.609M	$7.754M	$7.455M
YoY Change	22.67%	4.01%	24.33%
% of Gross Profit
Research & Development	$18.31M	$19.41M	$12.36M
YoY Change	815.35%	56.98%	33.61%
% of Gross Profit
Depreciation & Amortization	$360.0K	$357.0K	$344.0K
YoY Change	0.0%	3.78%	-35.22%
% of Gross Profit
Operating Expenses	$26.92M	$27.16M	$19.82M
YoY Change	11.41%	37.06%	29.96%
Operating Profit	-$26.84M	-$27.09M	-$19.74M
YoY Change	11.45%	37.2%	30.11%
Interest Expense	$141.0K	$193.0K	$315.0K
YoY Change	-50.7%	-38.73%	90.91%
% of Operating Profit
Other Income/Expense, Net	-$132.0K	-$126.0K	-$125.0K
YoY Change	-7.69%	0.8%	165.96%
Pretax Income	-$26.87M	-$27.16M	-$19.89M
YoY Change	9.23%	36.55%	29.16%
Income Tax
% Of Pretax Income
Net Earnings	-$26.87M	-$27.16M	-$19.89M
YoY Change	9.24%	36.54%	29.13%
Net Earnings / Revenue	-35832.0%	-36208.0%	-26517.33%
Basic Earnings Per Share			-$0.71
Diluted Earnings Per Share	-$902.3K	-$942.7K	-$0.71
COMMON SHARES
Basic Shares Outstanding	30.27M shares	29.32M shares	28.01M shares
Diluted Shares Outstanding			28.01M shares

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$165.5M	$188.6M	$236.6M
YoY Change	-23.7%	-20.29%	53.94%
Cash & Equivalents	$53.69M	$38.24M	$40.79M
Short-Term Investments	$111.9M	$150.4M	$195.8M
Other Short-Term Assets	$8.800M	$8.800M	$1.900M
YoY Change	450.0%	363.16%	0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$174.4M	$197.5M	$238.5M
YoY Change	-20.23%	-17.21%	53.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.26M	$11.21M	$19.71M
YoY Change	-36.26%	-43.16%	1.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change
Other Assets	$888.0K	$216.0K	$216.0K
YoY Change	314.95%	0.0%	-11.11%
Total Long-Term Assets	$12.72M	$12.00M	$20.51M
YoY Change	-31.05%	-41.49%	2.38%
TOTAL ASSETS
Total Short-Term Assets	$174.4M	$197.5M	$238.5M
Total Long-Term Assets	$12.72M	$12.00M	$20.51M
Total Assets	$187.1M	$209.5M	$259.0M
YoY Change	-21.07%	-19.13%	47.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.079M	$5.573M	$3.307M
YoY Change	36.79%	68.52%	58.31%
Accrued Expenses	$14.35M	$14.97M	$5.925M
YoY Change	155.19%	152.61%	47.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.600M	$3.500M	$3.300M
YoY Change	9.09%	6.06%	1000.0%
Total Short-Term Liabilities	$21.98M	$24.04M	$12.49M
YoY Change	84.39%	92.52%	94.31%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$1.000M	$4.500M
YoY Change	-100.0%	-77.78%	800.0%
Other Long-Term Liabilities	$0.00	$100.0K	$5.200M
YoY Change	-100.0%	-98.08%	-1.89%
Total Long-Term Liabilities	$0.00	$100.0K	$9.700M
YoY Change	-100.0%	-98.97%	67.24%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.98M	$24.04M	$12.49M
Total Long-Term Liabilities	$0.00	$100.0K	$9.700M
Total Liabilities	$27.66M	$30.78M	$22.15M
YoY Change	30.28%	38.99%	80.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$475.6M	-$448.7M	-$352.2M
YoY Change	26.24%	27.42%	28.43%
Common Stock	$635.1M	$627.5M	$588.8M
YoY Change	7.22%	6.57%	34.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$159.4M	$178.7M	$236.9M
YoY Change
Total Liabilities & Shareholders Equity	$187.1M	$209.5M	$259.0M
YoY Change	-21.07%	-19.13%	47.39%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$26.87M	-$27.16M	-$19.89M
YoY Change	9.24%	36.54%	29.13%
Depreciation, Depletion And Amortization	$360.0K	$357.0K	$344.0K
YoY Change	0.0%	3.78%	-35.22%
Cash From Operating Activities	-$24.29M	-$21.19M	-$15.68M
YoY Change	48.74%	35.15%	20.37%
INVESTING ACTIVITIES
Capital Expenditures	-$1.210M	$296.0K	$690.0K
YoY Change	303.33%	-57.1%	-61.69%
Acquisitions
YoY Change
Other Investing Activities	$37.81M	-$28.28M	-$143.9M
YoY Change	28.87%	-80.34%	-179912.5%
Cash From Investing Activities	$36.59M	-$28.57M	-$144.4M
YoY Change	26.0%	-80.21%	8265.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$26.22M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.160M	$25.00M	-$603.0K
YoY Change	-545.07%	-4246.1%	-76.47%
NET CHANGE
Cash From Operating Activities	-24.29M	-$21.19M	-$15.68M
Cash From Investing Activities	36.59M	-$28.57M	-$144.4M
Cash From Financing Activities	3.160M	$25.00M	-$603.0K
Net Change In Cash	15.46M	-$24.77M	-$160.7M
YoY Change	28.83%	-84.59%	827.96%
FREE CASH FLOW
Cash From Operating Activities	-$24.29M	-$21.19M	-$15.68M
Capital Expenditures	-$1.210M	$296.0K	$690.0K
Free Cash Flow	-$23.08M	-$21.49M	-$16.37M
YoY Change	43.98%	31.26%	10.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30273478	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q1	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1999-08-10
CY2017Q1	dei	Entity Information Date To Change Former Legal Or Registered Name EntityInformationDateToChangeFormerLegalOrRegisteredName	2005-04-19
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
CY2016Q4	rvnc	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	0	USD
CY2017Q1	rvnc	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	0	USD
CY2015Q4	rvnc	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	202050000	USD
CY2016Q1	rvnc	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41373000	USD
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2016Q4	rvnc	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64082000	USD
CY2017Q1	rvnc	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39317000	USD
CY2016Q1	rvnc	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-160677000	USD
CY2017Q1	rvnc	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-24765000	USD
CY2017Q1	rvnc	Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum	P12M
CY2016Q4	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	1872000	USD
CY2017Q1	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	983000	USD
CY2016Q4	rvnc	Financing Obligation Current FinancingObligationCurrent	3475000	USD
CY2017Q1	rvnc	Financing Obligation Current FinancingObligationCurrent	3502000	USD
CY2017Q1	rvnc	Financing Obligation Future Minimum Payments Due FinancingObligationFutureMinimumPaymentsDue	3830000	USD
CY2017Q1	rvnc	Financing Obligation Future Minimum Payments Duein Two Years FinancingObligationFutureMinimumPaymentsDueinTwoYears	949000	USD
CY2017Q1	rvnc	Financing Obligation Future Minimum Payments Remainderof Fiscal Year FinancingObligationFutureMinimumPaymentsRemainderofFiscalYear	2881000	USD
CY2017Q1	rvnc	Future Paymentsto Acquire Equipmenton Lease Remainderof Fiscal Year FuturePaymentstoAcquireEquipmentonLeaseRemainderofFiscalYear	100000	USD
CY2016Q1	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-14000	USD
CY2017Q1	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-60000	USD
CY2016Q1	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-19888000	USD
CY2017Q1	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-27156000	USD
CY2016Q1	rvnc	Noncash Interest Expense NoncashInterestExpense	112000	USD
CY2017Q1	rvnc	Noncash Interest Expense NoncashInterestExpense	83000	USD
CY2017Q1	rvnc	Working Capital Surplus WorkingCapitalSurplus	173400000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3754000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5573000	USD
CY2016Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-456000	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-194000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12418000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14967000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-45000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-98000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	598630000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	627475000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2977000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3155000	USD
CY2016Q4	us-gaap	Assets Assets	204360000	USD
CY2017Q1	us-gaap	Assets Assets	209454000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	192695000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	197453000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	182665000	USD
CY2017Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	181907000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	50000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	99000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	182710000	USD
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	182004000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	122026000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	150404000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	122026000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	150404000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63502000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38235000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	185500000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	188600000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28648954	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30129240	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28648954	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30129240	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	29000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	30000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19662000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27208000	USD
CY2016Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	179000	USD
CY2017Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	78000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3648000	USD
CY2017Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3576000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	344000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	357000	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2022000	USD
CY2016Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	203000	USD
CY2017Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	110000	USD
CY2016Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	310000	USD
CY2017Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	311000	USD
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P36M
CY2017Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2082000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.94
CY2016Q2	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	200000	USD
CY2016Q1	us-gaap	Financing Interest Expense FinancingInterestExpense	112000	USD
CY2017Q1	us-gaap	Financing Interest Expense FinancingInterestExpense	83000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	552000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1135000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	54000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2055000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-69000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	301000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1144000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	315000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	193000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	203000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	110000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	27289000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	30783000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	204360000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	209454000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19647000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	24042000	USD
CY2017Q1	us-gaap	Longterm Purchase Commitment Period LongtermPurchaseCommitmentPeriod	P7Y
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-603000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25001000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-144394000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28574000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15680000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21192000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21200000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-19888000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-27200000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-27156000	USD
CY2016Q1	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	147000	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	882000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	19819000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	27163000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19744000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27088000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	41983000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5947000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5763000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	5578000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	20644000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	4051000	USD
CY2016Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
CY2017Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
CY2017Q1	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2002-06-30
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	500000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	216000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	226000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-52000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	100000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	100000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-125000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-126000	USD
CY2016Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	37000	USD
CY2017Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	205000	USD
CY2016Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	224000	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	277000	USD
CY2016Q2	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1800000	USD
CY2016Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	159754000	USD
CY2017Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	36028000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	690000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	296000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.000
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7167000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8312000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26217000	USD
CY2016Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	15050000	USD
CY2017Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	7750000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	1000000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	509000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	210000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10585000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11205000	USD
CY2017Q1	us-gaap	Purchase Obligation PurchaseObligation	900000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	851000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	944000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2000000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12364000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	580000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	580000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-421543000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19409000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	502000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-448736000	USD
CY2016Q1	us-gaap	Revenues Revenues	75000	USD
CY2017Q1	us-gaap	Revenues Revenues	75000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7455000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7754000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2977000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3155000	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	122026000	USD
CY2017Q1	us-gaap	Short Term Investments ShortTermInvestments	150404000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	177071000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	178671000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28005611	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28808195	shares
CY2017Q1	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicis Settlement</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2009, the Company and Medicis Pharmaceutical Corporation, or Medicis, entered into a license agreement granting Medicis worldwide aesthetic and dermatological rights to the Company’s investigational botulinum toxin type A product candidates. In October 2012, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT002 injectable and RT001 topical from Medicis and for consideration payable by the Company to Medicis of up to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, comprised of (i) an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was paid in 2012, (ii) a proceeds sharing arrangement payment of </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;"> due upon specified capital raising achievements by the Company, of which </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2013 and </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> in 2014, and (iii) </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be paid upon the achievement of regulatory approval for RT002 injectable or RT001 topical by the Company, or Product Approval Payment. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the settlement provisions related to the proceeds sharing arrangement payment in (ii) above and Product Approval Payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company determined the fair value of its liability for the Product Approval Payment was </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">, which was measured by assuming a term of </font><font style="font-family:inherit;font-size:10pt;">3.25</font><font style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">1.55%</font><font style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </font><font style="font-family:inherit;font-size:10pt;">8.00%</font><font style="font-family:inherit;font-size:10pt;">. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in 2020. The Company did not make any payments under the Product Approval Payment during </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of Condensed Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include accruals, stock-based compensation, the fair value of derivative liability, impairment of long-lived assets, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001479290-17-000023-index-headers.html	Edgar Link	pending
0001479290-17-000023-index.html	Edgar Link	pending
0001479290-17-000023.txt	Edgar Link	pending
0001479290-17-000023-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rnvc-q117exhibit104.htm	Edgar Link	pending
rvnc-20170331.xml	Edgar Link	completed
rvnc-20170331.xsd	Edgar Link	pending
rvnc-20170331_cal.xml	Edgar Link	unprocessable
rvnc-20170331_def.xml	Edgar Link	unprocessable
rvnc-20170331_lab.xml	Edgar Link	unprocessable
rvnc-20170331_pre.xml	Edgar Link	unprocessable
rvnc-q117exhibit1025.htm	Edgar Link	pending
rvnc-q117exhibit311.htm	Edgar Link	pending
rvnc-q117exhibit312.htm	Edgar Link	pending
rvnc-q117exhibit321.htm	Edgar Link	pending
rvnc-q117exhibit322.htm	Edgar Link	pending
rvncq11710q.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2017 Q2 Form 10-Q Financial Statement

#000147929017000023 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2017 Q2 Form 10-Q Financial Statement

#000147929017000023 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc